BRCA2 and cancer: Our observation is in line with a study that measured a total of 20% of BRCA1 or BRCA2 deleterious germline mutations (Henouda et al., 2016) on forty Algerian primary invasive unrelated BC cases who attended the Anti-Cancer Center of Setif.